- Pooled analysis of data from the phase 3 LIBERTY AD SOLO 1 and 2 trials suggests that dupilumab (Dupixent) is associated with clinical benefit by several validated outcome measurements in patients with atopic dermatitis (AD) who did not achieve Investigator’s Global Assessment (IGA) score ≤1 (clear/almost clear skin).
Why this matters
- IGA score ≤1 is considered the regulatory standard for treatment success in US trials of patients with AD.
- In patients with IGA >1, dupilumab was associated with several superior results compared with placebo (P<.001 for all style="list-style-type:circle;">
- Eczema Area and Severity Index (EASI) improvements (−48.9% vs −11.3%).
- EASI-50 rates (49.6% vs 16.2%).
- EASI-75 rates (20.9% vs 4.8%).
- Pruritus numerical rating scale improvements (−35.2% vs −9.1%).
- Body surface area affected improvements (−23.1% vs −4.5%).
- Patient-oriented eczema measure ≥4-point improvement (57.4% vs 21.0%).
- Dermatology Life Quality Index ≥4-point improvement (59.3% vs 24.4%).
- Patients rating treatment as good, very good, or excellent (51.5% vs 24.0%).
- 674 patients with moderate to severe AD (278 treated with dupilumab every 2 weeks and 396 with placebo) who had IGA >1 at week 16 were included in this analysis.
- Funding: Sanofi Genzyme; Regeneron Pharmaceuticals, Inc.
- Post hoc analysis.